BIAF 1.51 bioAffinity Technologies, Inc.
| Range: | 1.15-3.62 | Vol Avg: | 104975 | Last Div: | 0 | Changes: | -0.72 |
| Beta: | 2.93 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Sep 01 2022 | Empoloyees: | 14 | ||
| CUSIP: | 09076W109 | CIK: | 0001712762 | ISIN: | US09076W1099 | Country: | US |
| CEO: | Ms. Maria Zannes J.D. | Website: | https://www.bioaffinitytech.com | ||||
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow